HIGH EXPRESSION OF CANCER TESTIS ANTIGENS MAGE-A, MAGE-C1/CT7, MAGE-C2/CT10, NY-ESO-1, AND GAGE IN ADVANCED SQUAMOUS CELL CARCINOMA OF THE LARYNX


Autoria(s): FIGUEIREDO, David L. A.; MAMEDE, Rui C. M.; SPAGNOLI, Giulio C.; SILVA JR., Wilson A.; ZAGO, Marco; NEDER, Luciano; JUNGBLUTH, Achim A.; SAGGIORO, Fabiano P.
Contribuinte(s)

UNIVERSIDADE DE SÃO PAULO

Data(s)

19/10/2012

19/10/2012

2011

Resumo

Background. Despite diagnostic and therapeutic advances in head and neck cancer, the 5-year survival of patients with laryngeal cancer has not improved in the last 30 years. Several recent studies indicate that specific targets for immunotherapeutic approaches can be useful in the control of cancer. There is considerable interest in the expression of cancer testis antigens in human cancers since they may serve as the basis for an immunologic approach to therapy. Methods. We evaluated by immunohistochemical analysis the expression of cancer testis antigens MAGE-A4 (57B), MAGE-C1 (CT7-33), MAGE-A1 (MA454), MAGE-A3 (M3H67), MAGE-C2 (CT10.5), NY-ESO-1 (E978), and GAGE (GAGE) in squamous cell carcinoma (SCC) of the larynx. Results. A total of 63 cases (57 men and 6 women) of laryngeal SCC were available for this study. The findings were correlated with the clinical course and laboratory data. Expression of at least 1 cancer testis antigen was detected in 42 of 63 of the laryngeal SCCs (67%). In 34 of 42 of the positive cases (81%) there was simultaneous expression of >= 2 cancer testis antigens. There was significant correlation between antigen expression and advanced tumor stage (stage III/IV) in cases with reactivity to only 1 antibody (p = .01) as well as in the cases with reactivity to >= 2 primary antibodies (>= 2 mAbs, p = .04). There was no association between survival and expression of any of the analyzed antigens. Conclusions. We find a high incidence of cancer testis antigen expression in SCCs of the larynx, which was correlated with advanced clinical stage. Our data indicate that cancer testis antigens could be valuable vaccine targets in laryngeal tumors, especially in those with a worse prognosis. (C) 2010 Wiley Periodicals, Inc. Head Neck 33: 702-707, 2011

FAPESP Fundacao de Amparo a Pesquisa do Estado de Sao Paulo

Identificador

HEAD AND NECK-JOURNAL FOR THE SCIENCES AND SPECIALTIES OF THE HEAD AND NECK, v.33, n.5, p.702-707, 2011

1043-3074

http://producao.usp.br/handle/BDPI/24683

10.1002/hed.21522

http://dx.doi.org/10.1002/hed.21522

Idioma(s)

eng

Publicador

WILEY-BLACKWELL

Relação

Head and Neck-journal for the Sciences and Specialties of the Head and Neck

Direitos

restrictedAccess

Copyright WILEY-BLACKWELL

Palavras-Chave #larynx cancer #tumor antigens #cancer testis antigens #squamous cell carcinoma #larynx #CANCER/TESTIS ANTIGENS #ANTIBODY 57B #TISSUES #GENES #IMMUNOTHERAPY #MELANOMA #HEAD #NECK #IDENTIFICATION #CORRELATE
Tipo

article

original article

publishedVersion